Study, "Soon" is a fairly vague word. You can't really mark that on your calendar. It is a word that would indicate that reimbursement was not a question of serious concern. At least not for this group of people. I don't know if Amarin has any type of manufacturing presence in France. I'll look tomorrow. I am unable to find any documents on the reimbursement process in China. By that I mean nothing Vascepa specific. Vazkepa is being recommended by clinical scientists who weigh in on what should be the standard of care for both the EU and specific countries within. Eventually this should force the bean counters to give. Sleven,
Market Data 
Markets 
AI
